Association of RDI with treatment outcome and patients' characteristics
| Impact of obinutuzumab RDI reduction >20% on outcome . | ||||
|---|---|---|---|---|
| Characteristic . | Overall (n = 130) . | RDI reduction of obinutuzumab dose . | P value* . | |
| >20% (n = 20) . | ≤20% (n = 110) . | |||
| ORR, n (%) | 111 (88%) | 11 (61%) | 100 (93%) | .001 |
| Median PFS | 33 mo | 17.2 mo | 37.3 mo | .001 |
| 24-mo PFS | 68% | 32% | 74% | <.001 |
| 36-mo PFS | 49% | 32% | 52% | <.001 |
| Median TTNT | 40 mo | 24.4 mo | NR | .001 |
| 24-mo TTNT | 75% | 57% | 79% | .001 |
| 36-mo TTNT | 54% | 34% | 58% | .001 |
| Impact of obinutuzumab RDI reduction >20% on outcome . | ||||
|---|---|---|---|---|
| Characteristic . | Overall (n = 130) . | RDI reduction of obinutuzumab dose . | P value* . | |
| >20% (n = 20) . | ≤20% (n = 110) . | |||
| ORR, n (%) | 111 (88%) | 11 (61%) | 100 (93%) | .001 |
| Median PFS | 33 mo | 17.2 mo | 37.3 mo | .001 |
| 24-mo PFS | 68% | 32% | 74% | <.001 |
| 36-mo PFS | 49% | 32% | 52% | <.001 |
| Median TTNT | 40 mo | 24.4 mo | NR | .001 |
| 24-mo TTNT | 75% | 57% | 79% | .001 |
| 36-mo TTNT | 54% | 34% | 58% | .001 |
| Impact of patients’ characteristic on obinutuzumab RDI reduction > 20% . | |||||
|---|---|---|---|---|---|
| Characteristic . | Overall (n = 130) . | RDI reduction of obinutuzumab dose . | |||
| >20% (n = 20) . | ≤20% (n = 110) . | P value* . | Q value† . | ||
| ECOG PS in class, n (%) | .027 | .027 | |||
| 0-1 | 94 (72) | 10 (50) | 84 (76) | ||
| ≥2 | 36 (28) | 10 (50) | 26 (24) | ||
| ANC before treatment, median (range) | 3920 (313, 16 000) | 3200 (313, 9290) | 4100 (580, 16 000) | .018 | .29 |
| CIRS in class, n (%) | .085 | .56 | |||
| ≤6 | 49 (38) | 4 (20) | 45 (41) | ||
| >6 | 81 (62) | 16 (80) | 65 (59) | ||
| Impact of patients’ characteristic on obinutuzumab RDI reduction > 20% . | |||||
|---|---|---|---|---|---|
| Characteristic . | Overall (n = 130) . | RDI reduction of obinutuzumab dose . | |||
| >20% (n = 20) . | ≤20% (n = 110) . | P value* . | Q value† . | ||
| ECOG PS in class, n (%) | .027 | .027 | |||
| 0-1 | 94 (72) | 10 (50) | 84 (76) | ||
| ≥2 | 36 (28) | 10 (50) | 26 (24) | ||
| ANC before treatment, median (range) | 3920 (313, 16 000) | 3200 (313, 9290) | 4100 (580, 16 000) | .018 | .29 |
| CIRS in class, n (%) | .085 | .56 | |||
| ≤6 | 49 (38) | 4 (20) | 45 (41) | ||
| >6 | 81 (62) | 16 (80) | 65 (59) | ||